JB/CALL/IDORSIA/4.25/0.3333/20.12.24 | Market Closed - Swiss Exchange 11:20:00 2024-07-03 EDT | ||
| 0.127 CHF | -9.93% |
|
| Current month | +7.63% | ||
| 1 month | -45.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 0.127 | -9.93% |
| 24-07-02 | 0.141 | +18.49% |
| 24-07-01 | 0.119 | +0.85% |
| 24-06-28 | 0.118 | -0.84% |
| 24-06-27 | 0.119 | -3.25% |
Delayed Quote Swiss Exchange
Last update July 03, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | Bank Julius Bär |
| IDXDJB | |
| ISIN | CH1286513010 |
| Date issued | 2023-09-12 |
| Strike | 4.25 CHF |
| Maturity | 2024-12-20 (170 Days) |
| Parity | 3 : 1 |
| Emission price | 0.42 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.55 CHF |
|---|---|
| Lowest since issue | 0.118 CHF |
| Spread | 0.01 CHF |
| Spread % | 7.87% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.28
CHF
Average target price
1.692
CHF
Spread / Average Target
-25.77%
- Stock Market
- Warrants
- IDXDJB Warrant
